| Literature DB >> 34831459 |
Giovanna Morello1, Ambra Villari1, Antonio Gianmaria Spampinato1, Valentina La Cognata1, Maria Guarnaccia1, Giulia Gentile1, Maria Teresa Ciotti2, Pietro Calissano3, Velia D'Agata4, Cinzia Severini2, Sebastiano Cavallaro1.
Abstract
Neuronal apoptosis and survival are regulated at the transcriptional level. To identify key genes and upstream regulators primarily responsible for these processes, we overlayed the temporal transcriptome of cerebellar granule neurons following induction of apoptosis and their rescue by three different neurotrophic factors. We identified a core set of 175 genes showing opposite expression trends at the intersection of apoptosis and survival. Their functional annotations and expression signatures significantly correlated to neurological, psychiatric and oncological disorders. Transcription regulatory network analysis revealed the action of nine upstream transcription factors, converging pro-apoptosis and pro-survival-inducing signals in a highly interconnected functionally and temporally ordered manner. Five of these transcription factors are potential drug targets. Transcriptome-based computational drug repurposing produced a list of drug candidates that may revert the apoptotic core set signature. Besides elucidating early drivers of neuronal apoptosis and survival, our systems biology-based perspective paves the way to innovative pharmacology focused on upstream targets and regulatory networks.Entities:
Keywords: apoptosis; disease; drug repurposing; drug targets; functional enrichment; neurotrophic factors; regulatory network; survival; transcriptional analysis
Mesh:
Substances:
Year: 2021 PMID: 34831459 PMCID: PMC8620386 DOI: 10.3390/cells10113238
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Venn diagram showing the number of genes differentially expressed in CGNs over time following induction of apoptosis (K5 vs. K25) or following rescue by SP, Pacap and Igf1. Of note, 262 genes (303 probes) were differentially expressed in all experimental conditions.
Figure 2Heat maps showing the 175 core set genes, which were deregulated in CGNs during apoptosis or rescue by GFs and showed opposite expression in at least one-time point. Among them, 117 genes showed an opposite expression pattern at 0.5 h, 78 genes at 1 h and 67 genes at 3 h. Fold changes are shown by colors.
Figure 3PPI network analysis. The PPI network for the 175 core set genes containing 187 nodes and 2668 interactions was constructed using the STRING website and visualized by Cytoscape (version: 3.8.2,) by mapping the “degree parameter” to node size. As the node size increased, the value of the connectivity degree of node genes increased. Proteins with a degree connectivity of >50 represent the most significant nodes in the PPI network and are colored from orange to red based on their node degree. Cebpb is the most interconnected node (hub) in the network and is colored in yellow. Differently colored “edges” indicate the type of evidence supporting each interaction: dark purple, co-expression; light purple, physical interaction; light blue, co-localization; light green, shared protein domain; orange, predicted; grey, other.
Figure 4Temporal specific core set genes-related PPI networks. The three time-point (0.5, 1 and 3 h) specific core set genes-related PPI networks were constructed using the STRING website and visualized by Cytoscape (version: 3.8.2,) by mapping the “degree parameter” to node size. As the node size increased, the value of the connectivity degree of node genes increased. Light blue/red nodes indicate, respectively, down-/upregulated genes following treatment with all GFs compared with apoptotic CGNs (K5). Differently colored “edges” indicate the type of evidence supporting each interaction: dark purple, co-expression; light purple, physical interaction; light blue, co-localization; light green, shared protein domain; orange, predicted; grey, other.
Figure 5PPI network cluster analysis. (a) Sub-network analysis in the PPI network using MCODE identified 11 significant modules/clusters Cluster analysis in the PPI network resulted in 7 clusters, which include 72 nodes and 276 edges, and are enriched for several biological process GO terms. (b) Cluster 1, Cluster 2 and Cluster 3 of the top three network clusters in the sub-network analysis of PPI networks of core set genes. These clusters had the highest scores among the clusters. The cluster networks were visualized by Cytoscape by mapping the “degree parameter” to node size.
Figure 6The upstream regulatory network is predicted to regulate the expression of the survival-related gene signatures in CGNs. (a) Result summary of the regulatory analysis with iRegulon on up-regulated core set genes. (b) Result summary of the regulatory analysis with iRegulon on downregulated core set genes. In particular, the top transcription binding motifs and their associated transcription factors (filtered for TF differentially expressed in our analysis) are shown. (c) The whole overview of the regulatory network of 9 key TFs together with their core set candidate targets. The network was visualized by Cytoscape. Targets are in white circle nodes with purple borders and TF in green hexagon nodes. Regulons for each TF are represented by different edge colors.
Figure 7Time-course TF-gene regulatory networks revealed a common early and transient peak of transcription of upstream regulators modulating the expression of core set genes. Networks were visualized by Cytoscape. For each time-point, the node color is consistent with the logFC of each gene: genes in blue are downregulated by GF treatment, whereas the genes in red are upregulated. Targets are represented as circle nodes with purple borders and TF as green hexagon nodes. Regulons for each TF are represented by different edge colors. Target genes are grouped according to their biological functions.
Disease-based functional annotation enrichment results of core set genes. The table shows disease enrichment results for all diseases significantly enriched with an adjusted p-value < 0.05.
| Disease Class | Genes Number | |
|---|---|---|
| Vision ( | 4.9 × 10−3 | 15 |
| Psychiatric disorders | 1.4 × 10−2 | 29 |
| Hematological disease | 4.4 × 10−2 | 22 |
| Cardiovascular disease | 4.7 × 10−2 | 50 |
| Immune disease | 5.0 × 10−2 | 37 |
Disease genes from the “psychiatric disease” family and related disorders.
| Gene Symbol | Gene Name | Disease |
|---|---|---|
|
| ATPase H+/K+ transporting beta subunit | Bipolar Disorder |
|
| FAT atypical cadherin 4 | Bipolar Disorder |
|
| FK506 binding protein 5 | Depression, affective psychoses, post-traumatic stress disorder, bipolar disorders |
|
| Ras interacting protein 1 | Bipolar Disorder |
|
| Adrenoceptor alpha 1D | Several psychiatric disorders |
|
| Aryl hydrocarbon receptor | Dementia |
|
| Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 | Bipolar Disorder |
|
| Cystathionine-beta-synthase | Dementia (AD), migraine disorders, schizophrenia |
|
| Death-associated protein | Schizophrenia |
|
| Gamma-aminobutyric acid type A receptor alpha-6-subunit | Schizophrenia, anxiety disorder |
|
| Inhibitor of DNA binding 2, HLH protein | Attention-deficit hyperactivity disorder |
|
| Insulin-induced gene 2 | Schizophrenia |
|
| Mannan binding lectin serine peptidase 2 | Dementia |
|
| Neurotensin receptor 1 | Schizophrenia, several psychiatric disorders |
|
| Neurotrophic receptor tyrosine kinase 1 | Several psychiatric disorders, autism, dementia |
|
| Nuclear receptor subfamily 4 group A member 1 | Schizophrenia, bipolar disorder |
|
| Nuclear receptor subfamily 4 group A member 3 | Schizophrenia, bipolar disorder |
|
| Nudix hydrolase 6 | Schizophrenia, bipolar disorder |
|
| Oligodendrocyte lineage transcription factor 2 | Schizophrenia, obsessive compulsive disorder, Tourette syndrome, dementia |
|
| Phosphodiesterase 9A | Depression |
|
| Phospholipase C delta 4 | Several psychiatric disorders |
|
| Progestin and adipoQ receptor family member 5 | Mental Disorders |
|
| Somatostatin receptor 2 | Several psychiatric disorders |
|
| Somatostatin receptor 3 | Several psychiatric disorders |
|
| Sprouty RTK signaling antagonist 4 | Schizophrenia |
|
| Synaptotagmin 6 | Mental Disorders |
|
| Transient receptor potential cation channel subfamily V member 1 | Autism |
|
| Vascular endothelial growth factor A | Major depressive disorder, autism, dementia |
|
| Zinc finger BED-type containing 4 | Schizophrenia, bipolar disorder |
The top 10 disease transcriptional signatures from iLINCS positively correlated with apoptotic CGN-related temporal expression changes.
| Disease State | Concordance | No. of Genes | |
|---|---|---|---|
| Lean | 0.64 | 1.50 × 10−3 | 21 |
| Adenocarcinoma | 0.58 | 1.17 × 10−6 | 159 |
| Hypernephroma | 0.50 | 1.23 × 10−2 | 159 |
| Carcinosarcoma | 0.49 | 3.01 × 10−2 | 159 |
| Renal_cell_carcinoma | 0.49 | 4.11 × 10−2 | 159 |
| Amyotrophic_lateral_sclerosis_ | 0.48 | 4.95 × 10−5 | 65 |
| No_atrial_fibrillation | 0.47 | 5.53 × 10−5 | 65 |
| Duchenne_muscular_dystrophy | 0.46 | 5.58 × 10−5 | 87 |
| Carcinoma | 0.42 | 1.22 × 10−4 | 80 |
| B-cell acute lymphoblastic leukemia | 0.42 | 3.19 × 10−2 | 26 |
List of the top 50 repurposable drug candidates with a potential to reverse apoptotic CGNs transcriptomic signature.
| Rank | Perturbation | Correlation Score | Mechanism of Action | Pharmacological Class | |
|---|---|---|---|---|---|
| 1 | Tozasertib | 2.08 × 10−5 | −0.98 | Aurora A/B/C kinases inhibitor | Chemotherapeutic |
| 2 | Necrostatin | 5.29 × 10−5 | −0.97 | RIP1 kinase inhibitor | Inhibitor of necroptosis |
| 3 | Tianeptine | 8.71 × 10−5 | −0.97 | Mu-type opioid receptor agonist | Tricyclic antidepressant |
| 4 | L-Sulforaphane | 1.00 × 10−4 | −0.97 | N/A | Anticancer |
| 5 | Pentoxifylline | 1.77 × 10−4 | −0.96 | Phosphodiesterase inhibitor | Hemorheological agent |
| 6 | Purmorphamine | 1.80 × 10−4 | −0.96 | Sonic Hedgehog agonist | - |
| 7 | Nicergoline | 1.91 × 10−4 | −0.96 | Alpha-1A adrenergic receptor antagonist | Vasodilator Agent |
| 8 | Pifithrin | 2.95 × 10−30 | −0.95 | p53 inhibitor | - |
| 9 | 5-Nonyloxytryptamine | 2.72 × 10−4 | −0.95 | Serotonin Receptor Agonist | - |
| 10 | Nifedipine | 2.79 × 10−4 | −0.95 | Specific blocker of L-type calcium channels | Antihypertensive, Antianginal |
| 11 | Tyrphostin | 1.54 × 10−15 | −0.92 | EGFR inhibitor | Antineoplastic |
| 12 | Parthenolide | 4.11 × 10−15 | −0.92 | NFKB inhibitor | - |
| 13 | Atorvastatin | 1.03 × 10−6 | −0.90 | HMG-CoA inhibitor | Statin (used to lower lipid levels and reduce the risk of cardiovascular disease) |
| 14 | Tanespimycin | 7.69 × 10−5 | −0.86 | HSP inhibitor | Anticancer |
| 15 | Monorden/Radicicol | 6.94 × 10−3 | −0.85 | HSP inhibitor | - |
| 16 | Azacyclonol | 1.55 × 10−2 | −0.81 | N/A | Antipsychotic |
| 17 | Rapamycin | 1.66 × 10−6 | −0.54 | mTOR inhibitor | Immunosuppressive |
| 18 | Amitriptyline | 7.97 × 10−6 | −0.50 | Norepinephrine and serotonin reuptake inhibitor | Tricyclic antidepressant |
| 19 | Allopurinol | 8.01 × 10−6 | −0.50 | Xanthine dehydrogenase/oxidase inhibitor | Xanthine Oxidase Inhibitors; Antigout Agents |
| 20 | Nortriptyline | 8.62 × 10−6 | −0.50 | Multiple | Tricyclic antidepressant |
| 21 | Bupropion | 1.57 × 10−5 | −0.49 | Norepinephrine/dopamine-reuptake inhibitor | Antidepressant |
| 22 | Roflumilast | 1.84 × 10−5 | −0.48 | Phosphodiesterase-4 inhibitor | Tricyclic antidepressant |
| 23 | Tranilast | 3.41 × 10−5 | −0.47 | Hematopoietic prostaglandin D synthase inhibitor | Antiallergic |
| 24 | Indomethacin | 3.10 × 10−5 | −0.47 | COX inhibitor | Non-steroidal anti-inflammatory drug |
| 25 | Nystatin | 3.24 × 10−5 | −0.47 | Channel-forming ionophore | Antifungal |
| 26 | Theophylline | 3.80 × 10−5 | −0.47 | Adenosine receptor antagonist | Bronchodilator |
| 27 | Citalopram | 3.85 × 10−5 | −0.47 | Reuptake of serotonin inhibitor | Antidepressant |
| 28 | Piracetam | 4.11 × 10−5 | −0.47 | Acetylcholine receptor agonist | Antipsychotic |
| 29 | Tacrolimus | 5.22 × 10−5 | −0.46 | Peptidyl-prolyl cis-trans isomerase FKBP1A, inhibitor | Immunosuppressive |
| 30 | Diazepam | 8.10 × 10−5 | −0.45 | GABA(A) Receptor positive allosteric modulator | Anxiolytic, sedative |
| 31 | Iproniazid | 7.33 × 10−5 | −0.45 | MAO inhibitor | Antidepressant |
| 32 | Promazine hydrochloride | 5.32 × 10−4 | −0.45 | Dopamine receptor antagonist | Antipsychotic |
| 33 | Cyproheptadine | 1.62 × 10−2 | −0.45 | Histamine receptor antagonist | Antiallergic |
| 34 | Dipyrone | 1.07 × 10−4 | −0.44 | N/A | Non-steroidal anti-inflammatory drug |
| 35 | Ethosuximide | 1.0 × 10−4 | −0.44 | T-type voltage sensitive calcium channels inhibitor | Anticonvulsants |
| 36 | Phenotiazine | 1.09 × 10−4 | −0.44 | N/A | Antipsychotic |
| 37 | Sulfanilamide | 1.12 × 10−4 | −0.44 | Dihydropteroate synthase inhibitor | Antibiotic |
| 38 | Clozapine | 1.35 × 10−4 | −0.44 | Dopamine/Serotonin antagonist | Antipsychotic |
| 39 | Lamotrigine | 1.68 × 10−4 | −0.43 | Multiple | Antiepileptic |
| 40 | Doxepin | 1.94 × 10−4 | −0.43 | Selective histamine H1 receptor blocker | Tricyclic antidepressant |
| 41 | Moclobemide | 2.22 × 10−4 | −0.43 | MAO inhibitor | Antidepressant |
| 42 | Rifabutin | 2.34 × 10−4 | −0.43 | DNA-dependent RNA polymerase inhibitor | Antibiotic |
| 43 | Rolipram | 2.15 × 10−4 | −0.43 | N/A | Antidepressant |
| 44 | Enaplapril | 2.75 × 10−4 | −0.42 | ACE inhibitor | Antihypertensive |
| 45 | Geldanamycin | 1.62 × 10−6 | −0.42 | N/A | Anticancer |
| 46 | Sibutramine | 3.77 × 10−4 | −0.41 | Dopamine, norepinephrine, serotonin transporter inhibitor | Antiobesity |
| 47 | Phenelzine | 9.79 × 10−4 | −0.38 | MAO inhibitor | Antidepressant |
| 48 | Thioridazine | 4.51 × 10−5 | −0.36 | Dopamine receptor antagonist | Antipsychotic |
| 49 | Artemisinin | 1.09 × 10−5 | −0.36 | N/A | Antimalarials |
| 50 | Withaferin A | 9.48 × 10−5 | −0.35 | N/A | Anticancer |